Human immunodeficiency virus (HIV)-specific CD8+ T cells persist in high frequencies in HIV-infected patients despite impaired CD4+ T helper response to the virus, but, unlike other differentiated effector cytotoxic T lymphocytes, most continue to express the tumor necrosis factor receptor family member CD27. Because the ligand for CD27 (CD70) is also overexpressed in HIV-infected hosts, we examined the nature of expression and potential functional consequences of CD27 expression on HIV-specific CD8+ T cells. Analysis of CD27+ and CD27− T cells derived from the same HIV-specific clone revealed that retention of CD27 did not interfere with acquisition of effector functions, and that after T cell receptor stimulation, CD27+ cells that concurrently were triggered via CD27 exhibited more resistance to apoptosis, interleukin 2 production, and proliferation than CD27− T cells. After transfer back into an HIV-infected patient, autologous HIV-specific CD27− T cells rapidly disappeared, but CD27+ T cells derived from the same clone persisted at high frequency. Our findings suggest that the CD27–CD70 interaction in HIV infection may provide CD27+ CD8+ T cells with a survival advantage and compensate for limiting or absent CD4+ T help to maintain the CD8 response.
Skip Nav Destination
Article navigation
6 December 2004
Article Contents
Article|
December 06 2004
CD27 Expression Promotes Long-Term Survival of Functional Effector–Memory CD8 + Cytotoxic T Lymphocytes in HIV-infected Patients
Adrian F. Ochsenbein,
Adrian F. Ochsenbein
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
Search for other works by this author on:
Stanley R. Riddell,
Stanley R. Riddell
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
4Department of Medicine, University of Washington, Seattle, WA 98195
Search for other works by this author on:
Michele Brown,
Michele Brown
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
Search for other works by this author on:
Lawrence Corey,
Lawrence Corey
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
4Department of Medicine, University of Washington, Seattle, WA 98195
Search for other works by this author on:
Gabriela M. Baerlocher,
Gabriela M. Baerlocher
2Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada V5Z 1L3
Search for other works by this author on:
Peter M. Lansdorp,
Peter M. Lansdorp
2Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada V5Z 1L3
3Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada V5Z 4E3
Search for other works by this author on:
Philip D. Greenberg
Philip D. Greenberg
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
4Department of Medicine, University of Washington, Seattle, WA 98195
5Department of Immunology, University of Washington, Seattle, WA 98195
Search for other works by this author on:
Adrian F. Ochsenbein
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
Stanley R. Riddell
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
4Department of Medicine, University of Washington, Seattle, WA 98195
Michele Brown
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
Lawrence Corey
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
4Department of Medicine, University of Washington, Seattle, WA 98195
Gabriela M. Baerlocher
2Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada V5Z 1L3
Peter M. Lansdorp
2Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada V5Z 1L3
3Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada V5Z 4E3
Philip D. Greenberg
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
4Department of Medicine, University of Washington, Seattle, WA 98195
5Department of Immunology, University of Washington, Seattle, WA 98195
Address correspondence to Adrian F. Ochsenbein, Dept. of Clinical Research and Institute for Medical Oncology, University of Berne, Murtenstrasse 35, 3010 Berne, Switzerland. Phone: 41-31-632-4114; Fax: 41-31-632-3297; email: [email protected]; or Philip D. Greenberg, University of Washington, BB1325 Health Sciences Building, Box 356527, Seattle, WA 98195. Phone: (206) 543-8306; Fax: (206) 685-3128; email: [email protected]
Abbreviations used in this paper: CFSE, carboxyfluorescein diacetate succinimidyl ester; LCL, lymphoblastoid cell line.
Received:
April 12 2004
Accepted:
October 20 2004
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2004
J Exp Med (2004) 200 (11): 1407–1417.
Article history
Received:
April 12 2004
Accepted:
October 20 2004
Citation
Adrian F. Ochsenbein, Stanley R. Riddell, Michele Brown, Lawrence Corey, Gabriela M. Baerlocher, Peter M. Lansdorp, Philip D. Greenberg; CD27 Expression Promotes Long-Term Survival of Functional Effector–Memory CD8+Cytotoxic T Lymphocytes in HIV-infected Patients . J Exp Med 6 December 2004; 200 (11): 1407–1417. doi: https://doi.org/10.1084/jem.20040717
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement